Potential application of injectable chitosan hydrogel treated with siRNA in chronic rhinosinusitis therapy

Cao,Cheng; Yan,Chunhong; Hu,Zhiqiang; Zhou,Shao

doi:10.3892/mmr.2015.4237

Potential application of injectable chitosan hydrogel treated with siRNA in chronic rhinosinusitis therapy

Authors:
- Cheng Cao
- Chunhong Yan
- Zhiqiang Hu
- Shao Zhou
View Affiliations

Affiliations: Department of Otorhinolaryngology, Yinzhou Hospital Affiliated to the Medical School of Ningbo University, Ningbo, Zhejiang 315000, P.R. China, Department of Otorhinolaryngology, No. 113 Hospital of PLA, Ningbo, Zhejiang 315000, P.R. China
Published online on: August 21, 2015 https://doi.org/10.3892/mmr.2015.4237
Pages: 6688-6694
Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chronic rhinosinusitis is a condition with severe clinical symptoms and limited therapeutic solutions. It has been reported that vascular endothelial growth factor (VEGF) can promote nasal epithelial cell growth and result in hyperplasia of the sinuses. Therefore, the downregulation of VEGF may inhibit the process of hyperplasia. In the present study, small interfering RNA (siRNA) targeting VEGF was used to silence the expression of VEGF, and injectable chitosan based hydrogel, which is suitable for sinus injection and exhibits long‑term retention, was prepared as the siRNA carrier. Human bronchial epithelial cells were cultured directly on the hydrogel to observe the biological performance in vitro. Further in vivo effects were investigated by the injection of the hydrogel into the sinus cavity. Following the introduction of siRNA introducing, the expression of VEGF in the bronchial epithelial cells was significantly suppressed at mRNA and protein levels. The number of living cells on the gel was significantly decreased, thus resulting in the inhibition of proliferation. However, the cytoskeletal arrangement of the remaining cells were not affected substantially. The hydrogel was able to retain the siRNA for an extended duration, which enabled a sustained supply of siRNA. The in vivo sinus mucosa analysis revealed that the siRNA was able to collocate with cells and the mucosa thickness was substantially decreased. In conclusion, the results of the present study suggested that injectable chitosan based hydrogel, treated with siRNA targeting VEGF, may be used as a convenient therapeutic option for chronic rhinosinusitis.

View Figures

View References

1	Obaseki D, Potts J, Joos G, Baelum J, Haahtela T, Ahlström M, Matricardi P, Kramer U, Gjomarkaj M, Fokkens W, et al: The relation of airway obstruction to asthma, chronic rhinosinusitis and age: Results from a population survey of adults. Allergy. 69:1205–1214. 2014. View Article : Google Scholar : PubMed/NCBI
2	Van Zele T, Holtappels G, Gevaert P and Bachert C: Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 28:192–198. 2014. View Article : Google Scholar : PubMed/NCBI
3	Saedi B, Sadeghi M, Akhavan-Khaleghi N and Seifmanesh H: Impact of endoscopic sinus surgery on the quality of life of patients with nasal polyposis. B-ENT. 10:59–65. 2014.PubMed/NCBI
4	Lee HS, Myers A and Kim J: Vascular endothelial growth factor drives autocrine epithelial cell proliferation and survival in chronic rhinosinusitis with nasal polyposis. Am J Respir Crit Care Med. 180:1056–1067. 2009. View Article : Google Scholar : PubMed/NCBI
5	Felipe AV, Oliveira J, Chang PY, Moraes AA, da Silva TD, Tucci-Viegas VM and Forones NM: RNA interference: A promising therapy for gastric cancer. Asian Pac J Cancer Prev. 15:5509–5515. 2014. View Article : Google Scholar : PubMed/NCBI
6	Sahin B, Fife J, Parmar MB, Valencia-Serna J, Gul-Uludağ H, Jiang X, Weinfeld M, Lavasanifar A and Uludağ H: siRNA therapy in cutaneous T-cell lymphoma cells using polymeric carriers. Biomaterials. 35:9382–9394. 2014. View Article : Google Scholar : PubMed/NCBI
7	Gu X, Ding F and Williams DF: Neural tissue engineering options for peripheral nerve regeneration. Biomaterials. 35:6143–6156. 2014. View Article : Google Scholar : PubMed/NCBI
8	Fu GF, Pan JC, Lin N, Hu HY, Tang WM, Xu JS, Wang XL, Xu XQ, Qiu T, Liu XY, et al: siRNA against KIR3DL1 as a potential gene therapeutic agent in controlling HIV-1 infection. Viral Immunol. 27:207–213. 2014. View Article : Google Scholar : PubMed/NCBI
9	Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B and Kjems J: Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther. 17:162–168. 2009. View Article : Google Scholar
10	Rudzinski WE and Aminabhavi TM: Chitosan as a carrier for targeted delivery of small interfering RNA. Int J Pharm. 399:1–11. 2010. View Article : Google Scholar : PubMed/NCBI
11	Gonçalves IC, Henriques PC, Seabra CL and Martins MC: The potential utility of chitosan micro/nanoparticles in the treatment of gastric infection. Expert Rev Anti Infect Ther. 12:981–992. 2014. View Article : Google Scholar : PubMed/NCBI
12	Han HD, Mora EM, Roh JW, Nishimura M, Lee SJ, Stone RL, Bar-Eli M, Lopez-Berestein G and Sood AK: Chitosan hydrogel for localized gene silencing. Cancer Biol Ther. 11:839–845. 2011. View Article : Google Scholar : PubMed/NCBI
13	Ma Z, Yang C, Song W, Wang Q, Kjems J and Gao S: Chitosan hydrogel as siRNA vector for prolonged gene silencing. J Nanobiotechnology. 12:232014. View Article : Google Scholar : PubMed/NCBI
14	Andersen MØ, Le DQS, Chen M, Nygaard JV, Moustapha K, Bünger C and Kjems J: Spatially controlled delivery of siRNAs to stem cells in implants generated by multi-component additive manufacturing. Adv Funct Mater. 23:5599–5607. 2013. View Article : Google Scholar
15	Ahn SK, Jeon SY, Khalmuratov R, Kim DJ, Kim JP, Park JJ and Hur DG: Rat model of staphylococcal enterotoxin B-induced rhinosinusitis. Clin Exp Otorhinolaryngol. 1:24–28. 2008. View Article : Google Scholar : PubMed/NCBI
16	Li SD, Chen YC, Hackett MJ and Huang L: Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther. 16:163–169. 2008. View Article : Google Scholar
17	Rimmer J, Fokkens W, Chong LY and Hopkins C: Surgical versus medical interventions for chronic rhinosinusitis with nasal polyps. Cochrane Database Syst Rev. 12:CD0069912014.PubMed/NCBI
18	Lee HS and Kim J: Constitutive expression of vascular endothelial cell growth factor (VEGF) gene family ligand and receptors on human upper and lower airway epithelial cells. Int Forum Allergy Rhinol. 4:8–14. 2014. View Article : Google Scholar : PubMed/NCBI
19	Matsune S, Ohori J, Yoshifuku K and Kurono Y: Effect of vascular endothelial growth factor on nasal vascular permeability. Laryngoscope. 120:844–848. 2010. View Article : Google Scholar : PubMed/NCBI
20	Burdick JA: Injectable gels for tissue/organ repair. Biomed Mater. 7:0202012012. View Article : Google Scholar : PubMed/NCBI
21	Punnia-Moorthy A: Evaluation of pH changes in inflammation of the subcutaneous air pouch lining in the rat, induced by carrageenan, dextran and staphylococcus aureus. J Oral Pathol. 16:36–44. 1987. View Article : Google Scholar : PubMed/NCBI
22	Fernandes M, Gonçalves IC, Nardecchia S, Amaral IF, Barbosa MA and Martins MC: Modulation of stability and mucoadhesive properties of chitosan microspheres for therapeutic gastric application. Int J Pharm. 454:116–124. 2013. View Article : Google Scholar : PubMed/NCBI
23	Kinis V, Ozbay M, Akdag M, Alabalık U, Gul A, Yılmaz B, Ozkan H and Topcu I: Effects of caffeic acid phenethyl ester on wound healing of nasal mucosa in the rat: An experimental study. Am J Otolaryngol. 35:482–486. 2014. View Article : Google Scholar : PubMed/NCBI